Logo image of XPEV

XPENG INC - ADR (XPEV) Stock Fundamental Analysis

NYSE:XPEV - US98422D1054 - ADR

22.7 USD
-1.63 (-6.7%)
Last: 8/27/2025, 8:24:23 PM
22.7 USD
0 (0%)
After Hours: 8/27/2025, 8:24:23 PM
Fundamental Rating

3

Overall XPEV gets a fundamental rating of 3 out of 10. We evaluated XPEV against 37 industry peers in the Automobiles industry. XPEV may be in some trouble as it scores bad on both profitability and health. XPEV is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XPEV has reported negative net income.
In the past 5 years XPEV always reported negative net income.
XPEV had negative operating cash flow in 4 of the past 5 years.
XPEV Yearly Net Income VS EBIT VS OCF VS FCFXPEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2B -4B -6B -8B -10B

1.2 Ratios

XPEV has a Return On Assets of -4.63%. This is in the better half of the industry: XPEV outperforms 67.57% of its industry peers.
XPEV has a Return On Equity of -14.11%. This is in the better half of the industry: XPEV outperforms 62.16% of its industry peers.
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROIC N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.51%
ROIC(3y)N/A
ROIC(5y)N/A
XPEV Yearly ROA, ROE, ROICXPEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 15.74%, XPEV is in the better half of the industry, outperforming 67.57% of the companies in the same industry.
In the last couple of years the Gross Margin of XPEV has grown nicely.
The Profit Margin and Operating Margin are not available for XPEV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
XPEV Yearly Profit, Operating, Gross MarginsXPEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

3

2. Health

2.1 Basic Checks

XPEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XPEV has more shares outstanding
The number of shares outstanding for XPEV has been increased compared to 5 years ago.
Compared to 1 year ago, XPEV has a worse debt to assets ratio.
XPEV Yearly Shares OutstandingXPEV Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
XPEV Yearly Total Debt VS Total AssetsXPEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

XPEV has an Altman-Z score of 1.51. This is a bad value and indicates that XPEV is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.51, XPEV is doing good in the industry, outperforming 70.27% of the companies in the same industry.
XPEV has a Debt/Equity ratio of 0.78. This is a neutral value indicating XPEV is somewhat dependend on debt financing.
XPEV's Debt to Equity ratio of 0.78 is in line compared to the rest of the industry. XPEV outperforms 48.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACC7.74%
XPEV Yearly LT Debt VS Equity VS FCFXPEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B 40B

2.3 Liquidity

XPEV has a Current Ratio of 1.14. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
XPEV has a Current ratio (1.14) which is in line with its industry peers.
XPEV has a Quick Ratio of 1.00. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.00, XPEV is in the better half of the industry, outperforming 64.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1
XPEV Yearly Current Assets VS Current LiabilitesXPEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

More info and screens

7

3. Growth

3.1 Past

XPEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.89%, which is quite impressive.
The Revenue has grown by 66.37% in the past year. This is a very strong growth!
The Revenue has been growing by 77.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)48.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.04%
Revenue 1Y (TTM)66.37%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%125.82%

3.2 Future

The Earnings Per Share is expected to grow by 23.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, XPEV will show a very strong growth in Revenue. The Revenue will grow by 29.34% on average per year.
EPS Next Y73.2%
EPS Next 2Y49.37%
EPS Next 3Y37.77%
EPS Next 5Y23.29%
Revenue Next Year94.5%
Revenue Next 2Y63.71%
Revenue Next 3Y46.44%
Revenue Next 5Y29.34%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
XPEV Yearly Revenue VS EstimatesXPEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50B 100B 150B
XPEV Yearly EPS VS EstimatesXPEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

XPEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 115.04, which means the current valuation is very expensive for XPEV.
XPEV's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. XPEV is cheaper than 67.57% of the companies in the same industry.
XPEV's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.80.
Industry RankSector Rank
PE N/A
Fwd PE 115.04
XPEV Price Earnings VS Forward Price EarningsXPEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XPEV Per share dataXPEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

XPEV's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XPEV's earnings are expected to grow with 37.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.37%
EPS Next 3Y37.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XPEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XPENG INC - ADR

NYSE:XPEV (8/27/2025, 8:24:23 PM)

After market: 22.7 0 (0%)

22.7

-1.63 (-6.7%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)08-19 2025-08-19/bmo
Earnings (Next)11-17 2025-11-17/bmo
Inst Owners15.84%
Inst Owner Change-7.73%
Ins Owners0.25%
Ins Owner ChangeN/A
Market Cap21.61B
Analysts78.75
Price Target24.72 (8.9%)
Short Float %9.78%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.15%
Min EPS beat(2)34.47%
Max EPS beat(2)47.83%
EPS beat(4)2
Avg EPS beat(4)18.03%
Min EPS beat(4)-8.69%
Max EPS beat(4)47.83%
EPS beat(8)4
Avg EPS beat(8)16.91%
EPS beat(12)4
Avg EPS beat(12)3.64%
EPS beat(16)6
Avg EPS beat(16)-1.06%
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-3.03%
Max Revenue beat(2)2.52%
Revenue beat(4)2
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-3.03%
Max Revenue beat(4)2.52%
Revenue beat(8)2
Avg Revenue beat(8)-2.71%
Revenue beat(12)2
Avg Revenue beat(12)-5.62%
Revenue beat(16)5
Avg Revenue beat(16)-2.9%
PT rev (1m)-1.66%
PT rev (3m)4.69%
EPS NQ rev (1m)10.48%
EPS NQ rev (3m)47.32%
EPS NY rev (1m)0.14%
EPS NY rev (3m)31.03%
Revenue NQ rev (1m)-0.98%
Revenue NQ rev (3m)8.51%
Revenue NY rev (1m)-1.23%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 115.04
P/S 2.57
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB 5.95
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)0.2
Fwd EY0.87%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.85
BVpS4.45
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.74%
FCFM N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.05%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1
Altman-Z 1.51
F-ScoreN/A
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)220.75%
Cap/Depr(5y)357.28%
Cap/Sales(3y)10.3%
Cap/Sales(5y)14.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.04%
EPS Next Y73.2%
EPS Next 2Y49.37%
EPS Next 3Y37.77%
EPS Next 5Y23.29%
Revenue 1Y (TTM)66.37%
Revenue growth 3Y24.87%
Revenue growth 5Y77.48%
Sales Q2Q%125.82%
Revenue Next Year94.5%
Revenue Next 2Y63.71%
Revenue Next 3Y46.44%
Revenue Next 5Y29.34%
EBIT growth 1Y22.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.93%
EBIT Next 3Y43.04%
EBIT Next 5Y30.46%
FCF growth 1Y-227.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-310.46%
OCF growth 3YN/A
OCF growth 5YN/A